Findings

What do systematic reviews say?

8 questions · 8 findings · 4 reviews · Headline outcomes only

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 3 · 37.5%Low 3 · 37.5%Moderate 1 · 12.5%High 0 · 0%

Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for people with borderline personality disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events · people who smoke

Bupropion showed no clear difference in serious adverse events compared with placebo/no pharmacological treatment (moderate certainty).

1 finding from 1 review

Antidepressants for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1.16 [0.9, 1.48]
23 studies · 10958 participants
Moderate

Serious adverse events · people who smoke

Bupropion plus nicotine replacement therapy (NRT) showed no clear difference in serious adverse events compared with NRT alone (low certainty).

1 finding from 1 review

Antidepressants for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1.52 [0.26, 8.89]
4 studies · 657 participants
Low

Serious adverse events · people who smoke

Bupropion plus varenicline showed no clear difference in serious adverse events compared with varenicline alone (low certainty).

1 finding from 1 review

Antidepressants for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1.23 [0.63, 2.42]
5 studies · 1268 participants
Low

Serious adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antidepressants for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 123 participants
Very low

Serious adverse events · children (4 to 18 years) with functional abdominal pain disorders

1 finding from 1 review

Antidepressants for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 115 participants
Very low

Serious adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antidepressants for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Very low

Serious adverse events between 0 and 16 weeks · predominantly knee osteoarthritis

Antidepressant showed no clear difference in serious adverse events between 0 and 16 weeks compared with placebo (low certainty).

1 finding from 1 review

Antidepressants for hip and knee osteoarthritis 2022 · Cochrane Headline outcomes only
RR 0.94 [0.46, 1.94]
9 studies · 2101 participants
Low